Pharmability doses first patient in Phase Ib trial of TIR-C and completes enrolment of first cohort
Pharmability today announced that the first patient has been dosed in the company’s first-in-human Phase Ib clinical trial of TIR-C in atopic dermatitis. Enrolment of the first cohort has also been completed. The study will generate the first clinical data on TIR-C, with a primary focus on safety and local tolerability.
STOCKHOLM, SWEDEN, October 6, 2026 – The first cohort comprises eight participants enrolled at the clinical site in Sweden. Once all participants in the cohort have completed treatment, safety data will be reviewed before the study proceeds to the next cohort.
The randomised, double-blind, placebo-controlled Phase Ib study evaluates the safety and local tolerability of cutaneously administered TIR-C in adults with atopic dermatitis. Secondary objectives include the characterisation of systemic exposure (pharmacokinetics), while exploratory endpoints are intended to provide an initial assessment of efficacy. Exploratory efficacy assessments will use established measures, including the Eczema Area and Severity Index (EASI), validated Investigator Global Assessment (vIGA) and patient-reported pruritus.
“Dosing the first patient in our Phase Ib trial marks Pharmability’s transition into clinical development and is the result of dedicated work by our team and partners,” says Leo Holmgren, CEO of Pharmability. “We now look forward to generating the first clinical data on TIR-C and advancing the study through the subsequent cohorts. I would also like to thank the patients, investigators and site staff who are making this study possible.”
For more information, please contact:
Leo Holmgren, CEO
Phone: Tfn: +46 70 049 18 42
Email: leo.holmgren@pharmability.com
About Pharmability
Pharmability (formerly TIRmed Pharma) is a clinical-stage biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a cutaneous oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief while reducing treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.
Pharmability is headquartered in Stockholm, Sweden. For more information, visit pharmability.com and follow Pharmability on LinkedIn.
Tags: